Last reviewed · How we verify
Palliative Chemotherapy
Palliative chemotherapy works by administering cytotoxic drugs to slow cancer growth and alleviate symptoms in patients with advanced or metastatic disease where cure is not the primary goal.
Palliative chemotherapy works by administering cytotoxic drugs to slow cancer growth and alleviate symptoms in patients with advanced or metastatic disease where cure is not the primary goal. Used for Advanced or metastatic cancer (specific cancer type not specified in available information).
At a glance
| Generic name | Palliative Chemotherapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Palliative chemotherapy uses conventional cytotoxic agents to target rapidly dividing cancer cells, thereby reducing tumor burden and associated symptoms such as pain, obstruction, or bleeding. Unlike curative chemotherapy regimens, palliative approaches prioritize quality of life and symptom management over aggressive dose intensification, often using lower doses or less frequent schedules to balance efficacy with tolerability.
Approved indications
- Advanced or metastatic cancer (specific cancer type not specified in available information)
Common side effects
- Myelosuppression (anemia, neutropenia, thrombocytopenia)
- Nausea and vomiting
- Fatigue
- Mucositis
- Alopecia
- Diarrhea or constipation
Key clinical trials
- Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer (NA)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy (NA)
- Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma (PHASE3)
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (PHASE1)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |